TABLE 2.

Baseline characteristics for ITT/safety population

Parameter	Single dose		Multidose
			Rhu-pGSN			Combined rhu-pGSN (N = 18)	Placebo (N = 7)
	Rhu-pGSN, 6 mg/kg (N = 6)	Placebo (N = 2)	6 mg/kg (N = 6)	12 mg/kg (N = 6)	24 mg/kg (N = 6)
Age (yr)
Mean (SD)	62.2 (16.6)	64.0 (2.8)	69.3 (11.4)	55.3 (8.8)	40.0 (19.6)	54.9 (18.0)	64.0 (17.6)
Median	63.0	64.0	69.5	53.5	34.0	56.5	77.0
Range	35.0–81.0	62.0–66.0	56.0–83.0	45.0–70.0	22.0–66.0	22.0–83.0	39.0–78.0
Sex, n (%)
Male	4 (66.7)	2 (100.0)	1 (16.7)	3 (50.0)	2 (33.3)	6 (33.3)	4 (57.1)
Female	2 (33.3)	0	5 (83.3)	3 (50.0)	4 (66.7)	12 (66.7)	3 (42.9)
Race, n (%)
White	6 (100.0)	2 (100.0)	6 (100.0)	6 (100.0)	6 (100.0)	18 (100.0)	7 (100.0)
Height (cm)
Mean (SD)	174.33 (7.31)	170.00 (7.07)	165.83 (10.15)	169.83 (8.93)	167.50 (10.48)	167.72 (9.43)	169.71 (6.60)
Median	174.50	170.00	162.50	169.50	165.50	165.00	170.00
Range	165.0–185.0	165.0–175.0	158.0–185.0	157.0–180.0	153.0–180.0	153.0–185.0	162.0–181.0
Weight (kg)
Mean (SD)	85.15 (13.81)	77.80 (11.31)	75.55 (14.35)	79.35 (19.35)	82.62 (13.49)	79.17 (15.27)	73.20 (14.62)
Median	88.50	77.80	80.50	80.40	82.05	82.05	74.20
Range	60.0–96.6	69.8–85.8	55.3–90.0	52.9–99.0	62.2–99.1	52.9–99.1	58.0–99.5
CURB-65 score
Median	1.0	1.0	1.5	0.0	0.0	0.0	1.0
Range	0–2	1–1	0–2	0–1	0–1	0–2	0–2
PSI class, n (%)
I	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)	2 (33.3)	3 (16.7)	2 (28.6)
II	3 (50.0)	1 (50.0)	2 (33.3)	3 (50.0)	4 (66.7)	9 (50.0)	1 (14.3)
III	1 (16.7)	1 (50.0)	3 (50.0)	2 (33.3)	0 (0.0)	5 (27.8)	3 (42.9)
IV	2 (33.3)	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)	1 (5.6)	1 (14.3)
V	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0	0
SOFA score
Median	1.5	2.0	1.0	0.5	1.0	1.0	1.0
Range	0–4	2–2	0–2	0–1	0–3	0–3	0–4
hsCRP (mg/liter)
Median	326.7 (N = 5)	395.9	62.1	4.8	9.05	11.75	62.3
Range	4.3–554.3	347–444.8	11.6–316.0	0.8–34.4	1.2–192.0	0.8–316.0	0.7–285.7